139 related articles for article (PubMed ID: 33389657)
1. A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor.
Hara R; Kawada H; Kikuti YY; Kikkawa E; Harada K; Aoyama Y; Ogiya D; Toyosaki M; Suzuki R; Machida S; Ohmachi K; Onizuka M; Ogawa Y; Masuda R; Iwazaki M; Nakamura N; Ando K
Int J Hematol; 2021 Apr; 113(4):606-610. PubMed ID: 33389657
[TBL] [Abstract][Full Text] [Related]
2. Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.
Lewandowski K; Kanduła Z; Gniot M; Paczkowska E; Nawrocka PM; Wojtaszewska M; Janowski M; Mariak M; Handschuh L; Kozlowski P
Ann Hematol; 2022 Dec; 101(12):2665-2677. PubMed ID: 36266510
[TBL] [Abstract][Full Text] [Related]
3. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.
Kittur J; Knudson RA; Lasho TL; Finke CM; Gangat N; Wolanskyj AP; Li CY; Wu W; Ketterling RP; Pardanani A; Tefferi A
Cancer; 2007 Jun; 109(11):2279-84. PubMed ID: 17440984
[TBL] [Abstract][Full Text] [Related]
4. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
Yönal İ; Dağlar-Aday A; Akadam-Teker B; Yılmaz C; Nalçacı M; Yavuz AS; Sargın FD
Turk J Haematol; 2016 Jun; 33(2):94-101. PubMed ID: 25913509
[TBL] [Abstract][Full Text] [Related]
5. Occurrence of JAK2V617F mutation in previously triple negative essential thrombocythemia.
Benetatos L
Leuk Lymphoma; 2017 Feb; 58(2):503-504. PubMed ID: 27348300
[No Abstract] [Full Text] [Related]
6. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
[TBL] [Abstract][Full Text] [Related]
7. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation.
Gau JP; Chen CC; Chou YS; Liu CJ; Yu YB; Hsiao LT; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH
Blood Cells Mol Dis; 2015 Jun; 55(1):36-9. PubMed ID: 25976465
[TBL] [Abstract][Full Text] [Related]
8. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
[TBL] [Abstract][Full Text] [Related]
9. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
[TBL] [Abstract][Full Text] [Related]
10. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
[TBL] [Abstract][Full Text] [Related]
11. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
[TBL] [Abstract][Full Text] [Related]
12. Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms.
Hu L; Pu L; Ding Y; Li M; Cabanero M; Xie J; Zhou D; Yang D; Zhang C; Wang H; Zhai Z; Ru X; Li J; Xiong S
Hematology; 2017 Jul; 22(6):354-360. PubMed ID: 27976991
[TBL] [Abstract][Full Text] [Related]
13. Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
Chen P; Ouyang J; Liang J; Yu X; Huang B
Clin Lab; 2016 Aug; 62(8):1477-1481. PubMed ID: 28164603
[TBL] [Abstract][Full Text] [Related]
14. Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm.
Li ZC; Fu HJ; Wang ZM; Yang S; Xu HZ
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706633
[TBL] [Abstract][Full Text] [Related]
15. JAK2V617F mutation is associated with special alleles in essential thrombocythemia.
Hsiao HH; Liu YC; Tsai HJ; Lee CP; Hsu JF; Lin SF
Leuk Lymphoma; 2011 Mar; 52(3):478-82. PubMed ID: 21281225
[TBL] [Abstract][Full Text] [Related]
16. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
17. Thrombocytosis in rheumatoid arthritis: JAK2V617F-positive essential thrombocythemia.
Ayvaz OC; Yavasoglu I; Kadikoylu G; Bozkurt G; Bolaman Z
Rheumatol Int; 2012 Jan; 32(1):269-71. PubMed ID: 21243496
[TBL] [Abstract][Full Text] [Related]
18. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
19. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
20. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Alvarez-Larrán A; Angona A; Martínez-Avilés L; Bellosillo B; Besses C
Leuk Res; 2012 Mar; 36(3):324-6. PubMed ID: 22001278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]